

Jorge A GÃ³mez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/219649/publications.pdf>

Version: 2024-02-01

18
papers

185
citations

1307594

7
h-index

1058476

14
g-index

20
all docs

20
docs citations

20
times ranked

165
citing authors

#	ARTICLE	IF	CITATIONS
1	Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 17, 5603-5613.	3.3	3
2	Budget impact analysis of pneumococcal conjugate vaccines in Colombia. Response to letter to the editor. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 5-6.	1.4	0
3	Letter to the Editor Regarding: "Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants". <i>Infectious Diseases and Therapy</i> , 2022, , .	4.0	0
4	A cost-effectiveness analysis of PHiD-CV compared to PCV13 in a national immunization program setting in Tunisia. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	3.3	0
5	Budget impact analysis of pneumococcal conjugate vaccines in Colombia. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 255-263.	1.4	2
6	Response to article by Johnna Perdrizet et al., "Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants". <i>Human Vaccines and Immunotherapeutics</i> , 2021, , 1-3.	3.3	0
7	Herpes zoster epidemiology in Latin America: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2021, 16, e0255877.	2.5	19
8	How to assess for the full economic value of vaccines? From past to present, drawing lessons for the future. <i>Journal of Market Access & Health Policy</i> , 2020, 8, 1719588.	1.5	11
9	Response to article by Matthew Wasserman et al. (2018): "Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico". <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 570-571.	3.3	0
10	Impact assessment of the incorporation of the rotavirus vaccine in the province of San Luis "Argentina. <i>Epidemiology and Infection</i> , 2019, 147, e308.	2.1	2
11	Estimation of the real burden of invasive meningococcal disease in Argentina. <i>Epidemiology and Infection</i> , 2019, 147, e311.	2.1	7
12	PIN16 ESTIMATED ANNUAL IMPACT OF PNEUMOCOCCAL CONJUGATE VACCINE (PCV) IMMUNIZATION PROGRAM IN COLOMBIA (2011-2018). <i>Value in Health Regional Issues</i> , 2019, 19, S43.	1.2	2
13	Estimated Annual Health and Cost Impact of PHiD-CV Immunization Program in Brazil. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, e260-e265.	2.0	5
14	Estimación de la Relación Costo-Efectividad de las Vacunas Neumocócicas Conjugadas Prevenar-13 y Synflorix®, Utilizadas en Los Programas de Vacunación de Población Infantil Mexicana. <i>Value in Health Regional Issues</i> , 2016, 11, 76-84.	1.2	6
15	Cost effectiveness evaluation of a rotavirus vaccination program in Argentina. <i>Vaccine</i> , 2015, 33, 5684-5690.	3.8	8
16	Residual economic burden of Streptococcus pneumoniae- and nontypeable Haemophilus influenzae-associated disease following vaccination with PCV-7: A multicountry analysis. <i>Vaccine</i> , 2010, 28, G14-G22.	3.8	12
17	Surveillance for rotavirus in Argentina. <i>Journal of Medical Virology</i> , 2001, 65, 190-198.	5.0	72
18	Surveillance for rotavirus in Argentina. <i>Journal of Medical Virology</i> , 2001, 65, 190-8.	5.0	27